A
AKERO THERAPEUTICS INC
NASDAQ: AKRO (Akero Therapeutics, Inc.)
最近更新时间: 7小时之前54.23
-0.11 (-0.20%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Akero Therapeutics, Inc. | 看跌 | 看跌 |
AIStockmoo 评分
-1.1
| 分析师共识 | -3.5 |
| 内部交易活动 | NA |
| 价格波动 | -0.5 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | 2.0 |
| 平均 | -1.13 |
|
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 1.37% |
| 机构持股比例 | 109.31% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 56.00 (Jefferies, 3.26%) | 保留 |
| 中 | 54.00 (-0.42%) | |
| 低 | 54.00 (HC Wainwright & Co., -0.42%) | 保留 |
| 54.00 (Canaccord Genuity, -0.42%) | 保留 | |
| 平均值 | 54.67 (0.81%) | |
| 总计 | 3 保留 | |
| 平均价格@调整类型 | 54.01 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| HC Wainwright & Co. | 10 Oct 2025 | 54.00 (-0.42%) | 保留 | 53.88 |
| 04 Sep 2025 | 72.00 (32.77%) | 购买 | 44.03 | |
| Canaccord Genuity | 09 Oct 2025 | 54.00 (-0.42%) | 保留 | 54.08 |
| Jefferies | 09 Oct 2025 | 56.00 (3.26%) | 保留 | 54.08 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合